Drug Information for Loestrin 24 Fe (Warner Chilcott (US), LLC): NONCONTRACEPTIVE HEALTH BENEFITS

  • The following noncontraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral-contraceptive formulations containing doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.

    Effects on menses:

    • Increased menstrual cycle regularity
    • Decreased blood loss and decreased incidence of iron-deficiency anemia
    • Decreased incidence of dysmenorrhea

    Effects related to inhibition of ovulation:

    • Decreased incidence of functional ovarian cysts
    • Decreased incidence of ectopic pregnancies

    Effects from long-term use:

    • Decreased incidence of fibroadenomas and fibrocystic disease of the breast
    • Decreased incidence of acute pelvic inflammatory disease
    • Decreased incidence of endometrial cancer
    • Decreased incidence of ovarian cancer
  • Drug Information Provided by National Library of Medicine (NLM).